Literature DB >> 2475258

Direct activation of human B lymphocytes by Candida albicans-derived mannan antigen.

M Mangeney1, A Fischer, F Le Deist, J P Latgé, A Durandy.   

Abstract

We have studied the activation of human resting B cells by a carbohydrate antigen, mannan, with a polymannose branched repetitive structure. Mannan has been extracted from the cell wall of the Candida albicans yeast. For this purpose, dense G0 B lymphocytes were purified from tonsils. Mannan antigen was shown to trigger B cell activation, since an increase of cell volume and RNA synthesis occurred. B cell proliferation was observed following addition of recombinant interleukin 2, but not following addition of recombinant interleukin 4 or low-molecular-weight BCGF. The B cell activation appears to be mannan-specific since B cells obtained from mannan-sensitized subjects but not from unsensitized subjects were responsive. The observation that mannan antigen can directly activate specific dense B lymphocytes can be related to the previous observation that the in vitro anti-mannan antibody production does not require a cognate T-B cell interaction.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2475258     DOI: 10.1016/0008-8749(89)90081-6

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  3 in total

1.  Restricted heterogeneity of T lymphocytes in combined immunodeficiency with hypereosinophilia (Omenn's syndrome).

Authors:  G de Saint-Basile; F Le Deist; J P de Villartay; N Cerf-Bensussan; O Journet; N Brousse; C Griscelli; A Fischer
Journal:  J Clin Invest       Date:  1991-04       Impact factor: 14.808

2.  Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats.

Authors:  F De Bernardis; M Boccanera; D Adriani; E Spreghini; G Santoni; A Cassone
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

3.  Avidity of Aspergillus umbrosus IgG antibodies in farmer's lung disease.

Authors:  K Kaukonen; J Savolainen; M Viander; E O Terho
Journal:  Clin Exp Immunol       Date:  1994-01       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.